Proposal for the use of progression-free survival in unblinded randomized trials.

Progression-free survival is an attractive end point for clinical trials when an overall survival end point may be confounded by additional treatments administered after progression. When a trial is performed in an unblinded manner, however, there is the potential for bias between the treatment arms because of the subjective aspects of the progression end point. We discuss the magnitude of this potential bias and suggest methods for lessening it. We propose the carrying forward of any progression information to two designated time points for the statistical analysis for trials that are not blinded. This proposal, possibly combined with central review of progression scans for these two time points, essentially eliminates any bias, with little risk of major efficiency loss compared with using the reported progression times.

[1]  A. Berger,et al.  The effect of grouping on the power of the Mantel--Haenszel test for the comparison of survival rates , 1993 .

[2]  W. Haenszel,et al.  Statistical aspects of the analysis of data from retrospective studies of disease. , 1959, Journal of the National Cancer Institute.

[3]  K. Carroll,et al.  Optimizing randomized phase II trials assessing tumor progression. , 2007, Contemporary clinical trials.

[4]  M. Buyse Cornerstones of a well-designed phase III trial , 2003 .

[5]  M H Gail,et al.  Applicability of sample size calculations based on a comparison of proportions for use with the logrank test. , 1985, Controlled clinical trials.

[6]  M. Buyse,et al.  Overall survival is not a realistic end point for clinical trials of new drugs in advanced solid tumors: a critical assessment based on recently reported phase III trials in colorectal and breast cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  Douglas G Altman,et al.  Systematic reviews in health care: Assessing the quality of controlled clinical trials. , 2001, BMJ.

[8]  J. Cuzick The Efficiency of the Proportions Test and the Logrank Test for Censored Survival Data , 1982 .

[9]  C. Wilson,et al.  Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  T. Kaptchuk,et al.  Intentional Ignorance: A History of Blind Assessment and Placebo Controls in Medicine , 1998, Bulletin of the history of medicine.